Dicot has contracted Thermo Fisher Scientific for manufacturing of LIB-01
Press release: Uppsala, January 19, 2023. The pharmaceutical company Dicot has contracted Thermo Fisher Scientific, the world leader in serving science, to perform GMP manufacturing of the drug candidate LIB-01 for the upcoming clinical trials.
Dicot is developing a new potency drug with the aim to treat erectile dysfunction and premature ejaculation better than existing drugs. The company has previously announced its intention to start clinical studies with the drug candidate LIB-01 in mid-2023.
For GMP (Good Manufacturing Practice) manufacturing of study drug to be used in the phase 1 clinical trials, Dicot has contracted Thermo Fisher Scientific. The company provides industry-leading pharma services solutions for drug development and manufacturing.
“We are very happy to engage with such an experienced and highly regarded drug manufacturer as Thermo Fisher for this important step in our supply chain for the upcoming clinical trials”, says Elin Trampe, CEO of Dicot.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 7 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.
Correction of pressrelease: LIDDS announces preliminary outcome in the Rights Issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELE...
aXichem expects increased sales of aXivite within dietary supplements in the US and EU over the next twelve months
aXichem AB (publ), which develops and markets natural analogue industrial chemicals, announces that it expects significantly increased sales over the next twelve months of the company's natural analogue product phenylcapsaicin in the area of dietary supplements and nutraceuticals, where the produc...
aXichem förväntar ökad försäljning av aXivite inom kosttillskott i USA och EU under kommande tolv månader
aXichem AB (publ), som utvecklar och marknadsför naturanaloga industrikemikalier, meddelar att man förväntar en betydligt ökad försäljning de kommande tolv månaderna av bolagets naturanaloga produkt fenylcapsaicin inom området kosttillskott och nutraceutical...
Elicera Therapeutics recruits LifeSci Consulting as transaction advisor to assist the company in evaluating strategic partnering initiatives
Gothenburg, February 7, 2023 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties, using the company’s proprietary and commerciall...